TARS (Tarsus Pharmaceuticals) Short Percentage of Float


TARS Tarsus Pharmaceuticals Inc TARS
48 GF Score
Price $67.11
GF Value $201.69
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Tarsus Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TARS vs VERA, IDYA, MLYS: Short Percentage of Float Comparison

For the Biotechnology subindustry, Tarsus Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tarsus Pharmaceuticals Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Tarsus Pharmaceuticals's Short Percentage of Float falls into.


TARS
48GF Score
Tarsus Pharmaceuticals Inc TARS
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued. The current stock price of $67.11 is trading 66.7% below its estimated GF Value™ of $201.69. GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TARS:

  • Short Percentage of Float:
  • GF Value™: $201.69 vs. price of $67.11 (66.7% below fair value)
  • GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsus Pharmaceuticals Business Description

Address 15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
48GF Score

Get the complete analysis for TARS

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$67.11
Price
$201.69
GF Value